By exploiting a clinically relevant protocol involving PBMC restimulation with LCL, we generated EBV-specific bulk CD4+ T cell cultures characterized by an in vitro cytotoxic activity and a significant in vivo antitumor effect against a murine model of PTLD (Table 1). The gene discussed is CD4; the disease is post-transplant lymphoproliferative disease.